| Title |
RNAi, microRNAs, and human disease
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2006
|
| DOI | 10.1007/s00280-006-0318-2 |
| Pubmed ID | |
| Authors |
Scott M. Hammond |
| Abstract |
MicroRNAs (miRNAs) are short, noncoding RNAs that posttranscriptionally regulate gene expression. Over 300 miRNA genes have been identified in the human genome. We have undertaken the study of miRNA function in mammals. Using a custom microarray platform, we investigated miRNA expression patterns in mammalian development and in cancer. We found that many miRNAs are downregulated in cancer. On the other hand, several miRNA genes are overexpressed in tumor cell lines and primary tumors. Seven of these cancer-associated miRNAs are clustered in a single primary transcript termed chr13orf 25 or OncomiR-1. This cluster is located in a region amplified in lymphoma and several solid malignancies. Ectopic expression of these miRNAs in a mouse model of lymphoma accelerated disease progression. In addition, the lymphomas had reduced apoptosis and were more disseminated into secondary regions. This work establishes noncoding RNAs, and specifically miRNAs, as oncogenes in human cancers. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 33% |
| Germany | 1 | 8% |
| United Kingdom | 1 | 8% |
| Unknown | 6 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 75% |
| Scientists | 2 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Denmark | 2 | 2% |
| Germany | 1 | 1% |
| Austria | 1 | 1% |
| Australia | 1 | 1% |
| Russia | 1 | 1% |
| China | 1 | 1% |
| Unknown | 82 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 25% |
| Student > Ph. D. Student | 15 | 16% |
| Student > Master | 15 | 16% |
| Student > Bachelor | 8 | 9% |
| Professor > Associate Professor | 5 | 5% |
| Other | 16 | 18% |
| Unknown | 9 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 37 | 41% |
| Biochemistry, Genetics and Molecular Biology | 15 | 16% |
| Medicine and Dentistry | 14 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Immunology and Microbiology | 3 | 3% |
| Other | 6 | 7% |
| Unknown | 13 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2022.
All research outputs
#2,127,318
of 25,186,033 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#44
of 2,558 outputs
Outputs of similar age
#4,287
of 85,246 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 15 outputs
Altmetric has tracked 25,186,033 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,558 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 85,246 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.